References
- 1. Zhu D, Sorg JA, Sun X. Clostridioides difficile Biology: Sporulation, Germination, and Corresponding Therapies for C. difficile Infection. Front Cell Infect Microbiol. 2018;8:29.10.3389/fcimb.2018.00029
- 2. Polage CR, Solnick JV, Cohen SH. Nosocomial Diarrhea: Evaluation and Treatment of Causes Other Than Clostridium difficile. Clin Infect Dis. 2012;55:982-989.10.1093/cid/cis551
- 3. McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;67:1-48.10.1093/cid/cix1085
- 4. Hu MY, Katchar K, Kyne L, et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology. 2019;136:1206-1214.10.1053/j.gastro.2008.12.038
- 5. Gupta SB, Mehta V, Dubberke ER. Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence. Clin Infect Dis. 2016;63:730-734.10.1093/cid/ciw364
- 6. Bagdasarian N, Rao K, Malani PN, et al. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA. 2015;313:398-408.10.1001/jama.2014.17103
- 7. Wanahita A, Goldsmith EA, Marino BJ, et al. Clostridium difficile infection in patients with unexplained leukocytosis. M J Med. 2003;115:543.10.1016/S0002-9343(03)00420-0
- 8. Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile Infection. Clinical Infectious Diseases. 2008;46:32-42.10.1086/52186018177219
- 9. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile Infection in the United States. N Engl J Med. 2015;372:825-834.10.1056/NEJMoa140891325714160
- 10. Lee HC, Kim KO, Jeong YH, et al. Clinical Outcomes in Hospitalized Patients with Clostridium difficile Infection by Age Group. Korean J Gastroenterol. 2016;67:81-86.10.4166/kjg.2016.67.2.8126907483
- 11. Oyaro MO, Plants-Paris K, Bishoff D, et al. High rate of Clostridium difficile among young adults presenting with diarrhea at two hospitals in Kenya. International Journal of Infectious Diseases. 2018;74:24-28.10.1016/j.ijid.2018.06.014615292829960098
- 12. See I, Mu Y, Cohen J, et al. AP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis. 2014;58:1394-1400.10.1093/cid/ciu125469792624604900
- 13. Hall AJ, Curns AT, McDonald LC, et al. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999–2007. Clin Infect Dis. 2012;55:216-223.10.1093/cid/cis38622491338
- 14. Stevens VW, Nelson RE, Schwab-Daugherty EM, et al. Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection. JAMA. 2017;117:546-553.10.1001/jamainternmed.2016.9045
- 15. Mankal PK, Abed J, Latte-Naor S, Grinspan A, Kotler DP. Fidaxomicin and Fecal Microbiota Transplants for Severe Clostridium difficile Colitis. American Journal of Therapeutics. 2019;26:115-117.10.1097/MJT.000000000000057330601771
- 16. Bhangu A, Nepogodiev D, Gupta A, et al. Systematic review and meta-analysis of outcomes following emergency surgery for Clostridium difficile colitis. Br J Surg. 2012;99:1501-1513.10.1002/bjs.886822972525
- 17. Kaiser AM, Hogen R, Bordeianou L, et al. Clostridium Difficile Infection from a Surgical Perspective. J Gastrointest Surg. 2015;19:1363-1377.10.1007/s11605-015-2785-425917533
- 18. Ferrada P, Callcut R, Zielinski MD, et al. Loop Ileostomy Vs. Total Colectomy As Surgical Treatment For Clostridium Difficile Associated Disease: An Eastern Association for the Surgery of Trauma Multicenter Trial. J Trauma Acute Care Surg. 2017;83:36-40.10.1097/TA.0000000000001498599880928426557
- 19. Khalil MA, Bhatnagar SR, Feldman L, et al. Development and validation of a clinical risk calculator for mortality after colectomy for fulminant Clostridium difficile colitis. Journal of Trauma and Acute Care Surgery. 2019. [Epub ahead of print]